Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis

Table 2 Summary of the screening and surveillance recommendation from international guidelines for patients with inflammatory bowel disease

	ECCO 2008	BSG 2010	AGA 2010	ACG 2010
1st screening	8-10 yr	10 yr	Max 8 yr	8-10 yr
	Extensive: 2 yearly to 20 yr then annually	By risk: low 5 yr	1-3 yr
Surveillance interval	Left sided: 2 yearly starting at 15 yr	Intermediate 3 yr	More often at high risk e.g., PSC	1-2 yr
	PSC: 1 yr	High 1 yr
Random biopsy	Recommended	Recommended	Recommended	Recommended
Chromoendoscopy	Superior to white light endoscopy	≥ 33 if no chromo	≥ 33	≥ 33

ECCO: European Crohn’s and Colitis Organization; BSG: British Society of Gastroenterology; AGA: American Gastroenterological Association; ACG: American College of Gastroenterology; PSC: Primary sclerosing cholangitis. Modified from Ref [80].